Press Releases Year None2024202320222021202020192018 Mar 04, 2024 Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants Feb 27, 2024 Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Feb 15, 2024 Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 Feb 02, 2024 Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Feb 01, 2024 Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference Jan 30, 2024 Vaxcyte Announces Pricing of $750 Million Public Offering Jan 30, 2024 Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants Jan 29, 2024 Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older Jan 16, 2024 Vaxcyte Appoints Whitney Jones as Chief People Officer Jan 04, 2024 Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Displaying 11 - 20 of 20
Year None2024202320222021202020192018 Mar 04, 2024 Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants Feb 27, 2024 Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Feb 15, 2024 Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 Feb 02, 2024 Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Feb 01, 2024 Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference Jan 30, 2024 Vaxcyte Announces Pricing of $750 Million Public Offering Jan 30, 2024 Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants Jan 29, 2024 Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older Jan 16, 2024 Vaxcyte Appoints Whitney Jones as Chief People Officer Jan 04, 2024 Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Displaying 11 - 20 of 20